BSH 2019 | New therapies in AML with Steven Knapper

Name: New therapies in AML with Steven Knapper
Uploaded: 2019-04-02T17:52:23.000Z
Duration: 2 min 56 s
Description: Steven Knapper, DM, FRCPath, MRCP, BMBCh, Cardiff University, Cardiff, Wales, UK, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. He gives us an overview of new therapies in acute myeloid leukemia (AML), which has seen an explosion of new agents and approvals.

Steven Knapper • 2 Apr 2019

BSH 2019

Leukemia CPX-351 Cytarabine Daunorubicin Gemtuzumab ozogamicin Midostaurin

RATIFY

Steven Knapper, DM, FRCPath, MRCP, BMBCh, Cardiff University, Cardiff, Wales, UK, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. He gives us an overview of new therapies in acute myeloid leukemia (AML), which has seen an explosion of new agents and approvals.